It highlights the impact of GLP-1 agonists on gut microbiota composition, metabolic health, and inflammation, providing insights into their potential mechanisms and therapeutic benefits in obesity management. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.